NCT05010629 - 9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 14, 2021

Primary Completion Date

February 14, 2025

Study Completion Date

April 12, 2027

Conditions

Salivary Gland CancerRecurrent Salivary Gland CancerMetastatic CancerAdenoid Cystic Carcinoma

Interventions

DRUG

9-ING-41

Intravenous infusion

DRUG

Carboplatin

Intravenous infusion

Trial Locations (2)

Brigham and Women's Hospital, Boston

Dana Farber Cancer Institute, Boston